tradingkey.logo

Alpha Teknova Inc

TKNO

4.354USD

+0.114+2.68%
Market hours ETQuotes delayed by 15 min
232.64MMarket Cap
LossP/E TTM

Alpha Teknova Inc

4.354

+0.114+2.68%
More Details of Alpha Teknova Inc Company
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.
Company Info
Ticker SymbolTKNO
Company nameAlpha Teknova Inc
IPO dateJun 25, 2021
CEOMr. Stephen Gunstream
Number of employees173
Security typeOrdinary Share
Fiscal year-endJun 25
Address2451 Bert Drive
CityHOLLISTER
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code95023
Phone18316371100
Websitehttps://www.teknova.com/
Ticker SymbolTKNO
IPO dateJun 25, 2021
CEOMr. Stephen Gunstream
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Irene Davis
Ms. Irene Davis
Director
Director
1.69M
--
Mr. Stephen Gunstream
Mr. Stephen Gunstream
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.50K
+13.39%
Mr. Alexander Vos
Mr. Alexander Vos
Independent Director
Independent Director
126.72K
+74.98%
Mr. Damon Terrill
Mr. Damon Terrill
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
41.03K
--
Ms. Martha J. Demski
Ms. Martha J. Demski
Independent Director
Independent Director
25.07K
-24.19%
Dr. Paul D. Grossman
Dr. Paul D. Grossman
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
9.21K
--
Mr. Alexander C. Herzick
Mr. Alexander C. Herzick
Director
Director
--
--
Ms. Brett M. Robertson
Ms. Brett M. Robertson
Independent Director
Independent Director
--
--
Mr. J. Matthew Mackowski
Mr. J. Matthew Mackowski
Director
Director
--
--
Mr. Matthew C. Lowell
Mr. Matthew C. Lowell
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Irene Davis
Ms. Irene Davis
Director
Director
1.69M
--
Mr. Stephen Gunstream
Mr. Stephen Gunstream
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
243.50K
+13.39%
Mr. Alexander Vos
Mr. Alexander Vos
Independent Director
Independent Director
126.72K
+74.98%
Mr. Damon Terrill
Mr. Damon Terrill
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
41.03K
--
Ms. Martha J. Demski
Ms. Martha J. Demski
Independent Director
Independent Director
25.07K
-24.19%
Dr. Paul D. Grossman
Dr. Paul D. Grossman
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
9.21K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Lab Essentials
8.12M
82.87%
Clinical Solutions
1.16M
11.86%
Other
516.00K
5.27%
By RegionUSD
Name
Revenue
Proportion
United States
9.27M
94.66%
International
523.00K
5.34%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Lab Essentials
8.12M
82.87%
Clinical Solutions
1.16M
11.86%
Other
516.00K
5.27%
Shareholding Stats
Updated: Wed, Jul 9
Updated: Wed, Jul 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Telegraph Hill Partners
70.58%
Davis (Ted)
3.53%
Davis (Irene)
3.16%
UBS Financial Services, Inc.
2.17%
Balyasny Asset Management LP
1.57%
Other
19.00%
Shareholders
Shareholders
Proportion
Telegraph Hill Partners
70.58%
Davis (Ted)
3.53%
Davis (Irene)
3.16%
UBS Financial Services, Inc.
2.17%
Balyasny Asset Management LP
1.57%
Other
19.00%
Shareholder Types
Shareholders
Proportion
Private Equity
70.58%
Individual Investor
10.77%
Investment Advisor
5.23%
Hedge Fund
3.12%
Investment Advisor/Hedge Fund
2.40%
Research Firm
0.82%
Pension Fund
0.15%
Other
6.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
131
49.74M
93.07%
-991.18K
2025Q1
159
49.02M
94.72%
+9.59M
2024Q4
142
49.19M
92.33%
+11.09M
2024Q3
142
47.90M
89.93%
+8.81M
2024Q2
140
36.69M
87.73%
-3.53M
2024Q1
145
36.60M
90.14%
-2.50M
2023Q4
149
35.47M
91.35%
-3.28M
2023Q3
155
35.09M
90.51%
+4.53M
2023Q2
176
26.14M
92.65%
-5.67M
2023Q1
173
27.23M
97.10%
+13.65M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Telegraph Hill Partners
37.72M
70.58%
--
--
Apr 22, 2025
Davis (Ted)
1.89M
3.53%
--
--
Apr 22, 2025
Davis (Irene)
1.69M
3.16%
--
--
Apr 22, 2025
UBS Financial Services, Inc.
1.16M
2.17%
+46.45K
+4.17%
Mar 31, 2025
Balyasny Asset Management LP
836.96K
1.57%
-164.71K
-16.44%
Mar 31, 2025
Mackowski J Matthew
820.81K
1.54%
--
--
Apr 22, 2025
Lowell (Matthew)
820.81K
1.54%
+701.77K
+589.51%
Apr 22, 2025
The Vanguard Group, Inc.
573.45K
1.07%
+33.21K
+6.15%
Mar 31, 2025
CenterBook Partners LP
304.55K
0.57%
+304.55K
--
Mar 31, 2025
Wexford Capital LP
275.00K
0.51%
+275.00K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Nanotechnology ETF
0.6%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.01%
iShares Biotechnology ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares UltraPro Russell2000
0%
View more
ProShares Nanotechnology ETF
Proportion0.6%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Micro-Cap ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI